Description
VAGIFERON Pharmacodynamics
Combination preparation for intravaginal use.
VAGIFERON® has antiviral, immunomodulating, anti-inflammatory, antifungal, antimicrobial and antiprotozoal
(trichomonacid) action. Interferon alfa-2b has pronounced antiviral, immunomodulatory properties.
Metronidazole is an antiprotozoal and antibacterial drug, a derivative of 5-nitroimidazole. The mechanism of action consists in biochemical reduction of the 5-nitrogroup of metronidazole by intracellular transport proteins of anaerobic microorganisms and protozoa. The reduced 5-nitrogroup of metronidazole interacts with the DNA of the microbial cell, inhibiting the synthesis of their nucleic acids, which leads to the death of the bacteria. It is active against Trichomonas vaginalis, Gardnerella vaginalis, as well as against Gram-negative anaerobes Bacteroides spp. (including B. fragilis, B. dista-sonis, B. status, B. thetaotaomicron, B. vulgaris), Fusobacterium spp. and some Gram-negative anaerobes (sensitive strains of Eubacterium spp, Clostridium spp., Pepto-coccus niger., Peptostreptococcus spp., Mobiluncus spp. sensitive strains). Aerobic microorganisms and facultative anaerobes are insensitive to metronidazole.
Fluconazole has a highly specific fungicidal (antifungal) effect. It is active in mycosis, including those caused by Candida spp. (including generalized candidiasis against immunosuppression), Cryptococcus neoformans and Coccidioides immitis, Microsporum spp., Blastoyces dermatitidis. When administered intravaginally, it is particularly active against Candida albicans, to a lesser extent against Candida glabrata.
Indications
-bacterial vaginosis,
-bacterial (nonspecific) vaginitis,
Vaginitis, caused by a mixed infection (trichomonas, gardenenerella, yeast-like fungi, herpes simplex virus type 1 and 2, mycoplasma, ureaplasma) in combination therapy.
Contraindications .
Hypersensitivity to the drug components (including to nitroimidazole derivatives), pregnancy, children under 18 years of age (effectiveness and safety of drug administration has not been established).
Administration during pregnancy and lactation
The drug is not used during pregnancy.
Metronidazole penetrates into the breast milk. Breast-feeding during the period of taking the drug should be cancelled. Breast-feeding should be resumed not earlier than 48 hours after termination of the drug administration.
Dosage and administration method
- Intravaginal.
- 1 suppository in the evening (before going to sleep), for 10 days.
